Livzon Pharmaceutical Group (HK:1513) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Livzon Pharmaceutical Group Inc. has released its unaudited interim results for the first half of 2024, which are now available on the company’s and HKEx’s websites. This announcement follows the disclosure rules of The Stock Exchange of Hong Kong Limited and the full 2024 Interim Report will be accessible online and sent to H share holders opting for printed copies.
For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.